Women who have mutations in genes called BRCA1 and BRCA2 have a high risk of developing breast cancer, often at an early age. Regular mammograms are offered to high-risk women to allow for the early identification and treatment of tumours. However, because these women are of a young age, they often have denser breasts, which affect the ability of mammography to detect disease.
Martin Leach (The Institute of Cancer Research, London, UK) and colleagues looked at whether MRI would be more effective than mammography in detecting breast tumours in high-risk women. Between August 1997 and May 2004, the investigators recruited around 650 women at high risk of breast cancer, from 22 radiology and genetic centres throughout the UK. The women, aged 35 to 49 years, were offered annual MRI and X-ray mammography for between two and seven years.
They found that MRI was nearly twice as sensitive as X-ray mammography in detecting breast cancer in women that have a high genetic risk of the disease. X-ray mammography identified 40% of the tumours in the women, while MRI detected 77%. However, when mammography and MRI were combined, 94% of tumours were picked up in the women. The researchers also found that MRI screening was particularly effective for women known to carry the BRCA1 gene mutation, detecting 92% of tumours in women carrying this gene whereas X-ray mammography only detected 23%.
Professor Leach states: "Our results, taken with the two other major prospective studies, suggest that MRI screening is more effective than mammography in this high risk group, and combining the methods is very effective. Our study also showed that MRI is of most benefit in carriers of BRCA1 mutations." (Quote by e-mail; does not appear in published paper)
In an accompanying Comment Ellen Warner (Toronto-Sunnybrook Regional Cancer Centre, Ontario, Canada) points out: "Although there is now unequivocal evidence that surveillance MRI is significantly more sensitive than mammography for women at high hereditary risk and detects cancers at an earlier stage, it is not yet known whether it will lower mortality in this population."
Professor Martin Leach, Cancer Research UK Clinical MR Research Group, The Institute of Cancer Research martin.leach@icr.ac.uk and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, SURREY, SM2 5PT, UK. T) 020 8661 3338
The Medical Research Council Press Office on +44 (0) 20 7637 6011.
Dr Ros Eeles, Team Leader in Cancer Genetics (ICR) and Honorary Consultant (RMH), The Institute of rosalind.eeles@icr.ac.uk Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, SURREY, SM2 5PT, UK. T) 07770 985 331
Comment Dr Ellen Warner, Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, ellen.warner@tsrcc.on.ca Toronto, Ontario, M4N 3M5 CANADA. T) 416 480 4617
ressoffice@lancet.com Telephone: +44 (0)20 7424 4949/4249
press office@lancet.com
Please mention The Lancet as the source of this material
Issued by The Lancet
Press Office, New York
pressoffice@lancet.com Telephone: +44 (0)20 7424 4949/4249
Journal
The Lancet